4-(2-Amino-1-Hydroxyethyl) Benzene-1,2-Diol is a pharmaceutical ingredient whose molecular pharmacology encompasses primary target interactions, off-target binding to safety-relevant proteins, and concentration-response relationships that collectively determine whether pharmacologically-based or NOAEL-based OEL derivation methodology is more protective for occupationally exposed workers. The identification of the critical pharmacodynamic effect and its dose-response threshold in humans—from clinical pharmacology studies or clinical pharmacokinetic-pharmacodynamic modelling—provides a scientifically superior basis for OEL derivation compared to default interspecies extrapolation from animal toxicity data.
The pharmacologically-based OEL approach is used for 4-(2-Amino-1-Hydroxyethyl) Benzene-1,2-Diol when its receptor-mediated pharmacodynamic activity in humans produces the most sensitive adverse effect at doses below the NOAEL from general organ toxicity studies.
